2.52
0.07 (2.86%)
| Previous Close | 2.45 |
| Open | 2.45 |
| Volume | 156,053 |
| Avg. Volume (3M) | 396,554 |
| Market Cap | 129,171,136 |
| Price / Book | 6.03 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -0.960 |
| Total Debt/Equity (MRQ) | 1.67% |
| Current Ratio (MRQ) | 3.00 |
| Operating Cash Flow (TTM) | -15.63 M |
| Levered Free Cash Flow (TTM) | -15.19 M |
| Return on Assets (TTM) | -90.68% |
| Return on Equity (TTM) | -332.67% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | TuHURA Biosciences, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -4.0 |
| Average | -0.75 |
|
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 41.96% |
| % Held by Institutions | 8.43% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Suncoast Equity Management | 30 Sep 2025 | 104,409 |
| Sabal Trust Co | 31 Mar 2025 | 39,427 |
| 52 Weeks Range | ||
| Median | 8.00 (217.46%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Maxim Group | 14 Nov 2025 | 8.00 (217.46%) | Buy | 2.05 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |